FIELD: biotechnology.
SUBSTANCE: disclosed are immune cells comprising a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular domain, a transmembrane domain and an intracellular domain comprising a costimulatory endodomain, wherein the costimulatory endodomain comprises an intracellular signalling domain of 4-1BB/CD137 and five additional amino acids. Extracellular domain of CAR contains an antigen-binding domain specifically binding to glypican-3. Also disclosed are nucleic acids, vectors, compositions and methods of treating cancer using engineered immune cells containing CAR.
EFFECT: invention provides improved effectiveness of CAR-T and can be used for treating certain types of cancer.
49 cl, 19 dwg, 1 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
HLA-DR-BINDING CHIMERIC ANTIGEN RECEPTOR AND CAR-T CELL | 2019 |
|
RU2778890C1 |
IMPROVED IMMUNE CELLS WITH DOUBLE shRNA AND COMPOSITIONS CONTAINING THEM | 2019 |
|
RU2793922C2 |
MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
HLA-NON-RESTRICTED T-CELL RECEPTORS AND THEIR USE | 2019 |
|
RU2812917C2 |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | 2013 |
|
RU2729401C2 |
CHIMERIC RECEPTORS CONTAINING TRAF-6-INDUCING DOMAINS AND COMPOSITIONS AND METHODS RELATED TO THEM | 2016 |
|
RU2773159C2 |
METHODS OF PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2019 |
|
RU2822196C2 |
CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
Authors
Dates
2024-11-21—Published
2020-06-26—Filed